Czader M, Mazur J, Pettersson M, Liliemark J, Strömberg M, Christensson B, Tribukait B, Auer G, Ost A, Porwit A
Department of Pathology, Karolinska Hospital, Stockholm, Sweden.
Cancer. 1996 Mar 15;77(6):1180-8.
The biologic parameters, DNA ploidy and proliferative activity, have been suggested as prognostic factors in non-Hodgkin's lymphoma (NHL). However, reports on the prognostic importance of these factors in follicle center cell-derived (FCC) centroblastic/centrocytic (CB/CC) NHL patients with long follow-up are scarce.
Apoptotic fractions were quantified in 60 patients with CB/CC NHL by in situ labeling of DNA strand breaks in nuclei [TdT-mediated dUTP/dATP in situ 3'OH--end labeling (TUNEL)]. The findings were related to S-phase and MIB-1 counts, DNA ploidy, and clinical outcome.
In CB/CC NHL, the percentages of proliferating and apoptotic cells were lower than in reactive germinal centers (GC; P < 0.05; mean, 0.188 vs 3.263% and 19.05 vs. 69.4% for TUNEL and MIB-1 positive cells in CB/CC and GC, respectively). Significantly higher percentages of MIB-1 and TUNEL positive cells were observed in patients with complete remission when compared with the partial remission / no response group (P < 0.01). The size of proliferative and apoptotic fractions did not correlate with the overall survival of the patients. However, follicular and diffuse growth pattern, elevated serum lactic dehydrogenase, advanced stage, and age indicated a lower probability of 5- and 10-year survival.
The investigation of proliferative and apoptotic fractions in FCC lymphomas may help to define groups of patients to who would benefit from aggressive, high dose therapy protocols and patients to whom less aggressive strategies can be applied safely.
生物参数、DNA倍体和增殖活性已被认为是非霍奇金淋巴瘤(NHL)的预后因素。然而,关于这些因素在长期随访的滤泡中心细胞来源(FCC)中心母细胞/中心细胞(CB/CC)NHL患者中的预后重要性的报道很少。
通过对细胞核中DNA链断裂进行原位标记[TdT介导的dUTP/dATP原位3'OH末端标记(TUNEL)],对60例CB/CC NHL患者的凋亡分数进行定量分析。研究结果与S期和MIB-1计数、DNA倍体及临床结局相关。
在CB/CC NHL中,增殖细胞和凋亡细胞的百分比低于反应性生发中心(GC)(P<0.05;CB/CC和GC中TUNEL和MIB-1阳性细胞的平均值分别为0.188%对3.263%和19.05%对69.4%)。与部分缓解/无反应组相比,完全缓解患者中MIB-1和TUNEL阳性细胞的百分比显著更高(P<0.01)。增殖和凋亡分数的大小与患者的总生存期无关。然而,滤泡性和弥漫性生长模式、血清乳酸脱氢酶升高、晚期和年龄表明5年和10年生存率较低。
对FCC淋巴瘤中增殖和凋亡分数的研究可能有助于确定哪些患者群体将从积极的高剂量治疗方案中获益,哪些患者可以安全地采用不太积极的治疗策略。